Bradley Mark J. lessened its holdings in Johnson & Johnson (NYSE: JNJ – Get Rating) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,978 shares of the company stock after selling 734 shares during the period. Johnson & Johnson comprises approximately 3.4% of Bradley Mark J.’s portfolio, making the stock its 9th biggest position. Bradley Mark J.’s holdings in Johnson & Johnson were worth $ 5,128,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the company. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $ 26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $ 34,000. Jackson Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock worth $ 40,000 after acquiring an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after acquiring an additional 61 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after acquiring an additional 218 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.
JNJ stock opened at $ 169.46 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a 50 day moving average price of $ 178.10 and a 200 day moving average price of $ 172.79. Johnson & Johnson has a fifty-two week low of $ 155.72 and a fifty-two week high of $ 186.69. The stock has a market capitalization of $ 445.92 billion, a PE ratio of 22.84, a price-to-earnings-growth ratio of 3.36 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its earnings results on Tuesday, April 19th. The company reported $ 2.67 EPS for the quarter, beating the consensus estimate of $ 2.60 by $ 0.07. The company had revenue of $ 23.43 billion during the quarter, compared to analysts’ expectations of $ 23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $ 2.59 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were issued a $ 1.13 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 annualized dividend and a dividend yield of 2.67%. Johnson & Johnson’s payout ratio is 60.92%.
Several equities analysts have weighed in on the company. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their target price for the company from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Bank of America assumed coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Citigroup cut their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Raymond James raised their price target on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, Morgan Stanley lowered their price target on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $ 190.50.
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $ 12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider William Hait sold 29,699 shares of the stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company stock, valued at $ 14,729,724.88. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock valued at $ 13,895,302 in the last three months. 0.35% of the stock is owned by company insiders.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also:
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.